Vascular involvement in inflammatory bowel disease: Pathogenesis and clinical aspects

Digestive Diseases

Volumn 26, Issue 2, 2008, Pages 149-155

  Papa, Alfredo ^a,c   Scaldaferri, Franco ^a   Danese, Silvio ^b   Guglielmo, Simona ^a   Roberto, Italia ^a   Bonizzi, Michele ^a   Mocci, Giammarco ^a   Felice, Carla ^a   Ricci, Caterina ^a   Andrisani, Gianluca ^a   Fedeli, Giuseppe ^a   Gasbarrini, Giovanni ^a   Gasbarrini, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Coagulation; Crohn's disease; Inflammatory bowel disease; Thrombosis; Ulcerative colitis

Indexed keywords

ANTICOAGULANT AGENT; AZATHIOPRINE; CELL ADHESION MOLECULE; CYANOCOBALAMIN; FOROPAFANT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; LOW MOLECULAR WEIGHT HEPARIN; MERCAPTOPURINE; MESALAZINE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ANTICOAGULATION; ARTERY THROMBOSIS; CENTRAL VENOUS CATHETERIZATION; CLINICAL FEATURE; CROHN DISEASE; ENDOTHELIAL DYSFUNCTION; ENTERITIS; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INTESTINAL BLEEDING; INTESTINE INJURY; INTESTINE MUCOSA; LUNG EMBOLISM; MICROANGIOPATHY; PRIORITY JOURNAL; RECTUM HEMORRHAGE; REVIEW; RISK FACTOR; STEROID THERAPY; THROMBOEMBOLISM; ULCER HEALING; ULCERATIVE COLITIS; VASCULAR DISEASE; VASODILATATION; VEIN THROMBOSIS;

HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MICROCIRCULATION; THROMBOSIS;

EID: 42449091641     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000116773     Document Type: Review

References (54)

1. Fiocchi C: Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997;273:G769-G775.
2. Hatoum OA, Miura H, Binion DG: The vascular contribution in the pathogenesis of inflammatory bowel disease. Am J Physiol 2003;285:H1791-H1796.
3. Laroux FS, Grisham MB: Immunological basis of inflammatory bowel disease: role of the microcirculation. Microcirculation 2001;8:283-301.
4. Ossama A, Hatoum OA, Binion DG: The vasculature and inflammatory bowel disease. Contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis 2005;11:304-313.
5. Kirsner JB, Shorter RG: Inflammatory Bowel Disease. Baltimore, Williams & Wilkins, 1995.
6. Arfors KE, Rutili G, Svensjo E: Microvascular transport of macromolecules in normal and inflammatory conditions. Acta Physiol Scand Suppl 1979;463:93-103.
7. Granger DN, Kubes P: The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994;55:662-675.
8. Soriano A, Salas A, Salas A, Sans M, Gironella M, Elena M, Anderson DC, Pique JM, Panes J: VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest 2000;80:1541-1551.
9. Hatoum OA, Binion DG, Otterson MF, et al: Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology 2003;125:58-69.
10. Wakefield AJ, Sankey EA, Dhillon AP, et al: Granulomatous vasculitis in Crohn's disease. Gastroenterology 1991;100:1279-1287.
11. Dvorak AM, Monahan RA, Osage JE, et al: Crohn's disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Hum Pathol 1980;11:606-619.
12. Podolsky DK, Lobb R, King N, et al: Attenuation of colitis in the cottontop tamarin by anti-α4 integrin monoclonal antibody. J Clin Invest 1993;92:372-380.
13. Briskin M, Winsor-Hines D, Shyjan A, et al: Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110.
14. Binion DG, West GA, Volk EE, et al: Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998;352:1742-1746.
15. Talbot RW, Heppell J, Dozois RR, et al: Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140-145.
16. Sloan WP Jr, Bargen JA, Gage RB: Life histories of patients with chronic ulcerative colitis: a review of 2,000 cases. Gastroenterology 1968;54(suppl):819-822.
17. Graef V, Baggenstoss AH, Sauer WG, et al: Venous thrombosis occurring in non-specific ulcerative colitis. A necropsy study. Arch Intern Med 1966;117:377-382.
18. Bernestein CN, Blanchard JF, Houston DS, et al: The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430-434.
19. Grip O, Svensson PJ, Lindgren S: Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000;35:619-623.
20. Thompson NP, Wakefield AJ, Pounder RE: Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995;108:1011-1015.
21. Papa A, Danese S, Gasbarrini A, et al: Potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1403-1409.
22. Papa A, Danese S, Grillo A, Gasbarrini G, Gasbarrini A: Inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 2003;98:1247-1251.
23. Linderberg E, Jurnerot G, Huitfeldt B: Smoking in Crohn's disease: effect on localization and clinical course. Gut 1992;33:779-782.
24. Godet PG, May GR, Sutherland LR: Metaanalysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 1995;108:1011-1015.
25. Papa A, De Stefano V, Danese S, Gasbarrini A, Gasbarrini G: Thrombotic complications in inflammatory bowel disease: a multifactorial etiology. Am J Gastroenterol 2001;96:1301-1302.
26. Oldenburg B, Van Tuyl BA, van der Griend R, Fijnheer R, van Berge Henegouwen GP: Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci 2005;50:235-240.
27. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, Grisar J, Machold K, Scholz S, Vogelsang H, Novacek G: Is inflammatory bowel disease an independent and disease-specific risk factor for thromboembolism? Gut 2004;53:542-548.
28. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ: Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99:97-101.
29. Johns DR: Cerebrovascular complications of inflammatory bowel disease. Am J Gastroenterol 1991;86:367-370.
30. Maccini DM, Berg JC, Bell GA: Budd-Chiari syndrome and Crohn's disease. An unreported association. Dig Dis Sci 1989;34:1933-1936.
31. Keyser BJ, Hass AN: Retinal vascular disease in ulcerative colitis. Am J Ophthalmol 1994;118:395-396.
32. Hatoum OA, Spinelli KS, Abu-Hajir M, et al: Mesenteric venous thrombosis in inflammatory bowel disease. J Clin Gastroenterol 2005;39:27-31.
33. Umit H, Asil T, Celik Y, et al: Cerebral sinus thrombosis in patients with inflammatory bowel disease: a case report. World J Gastroenterol 2005;11:5404-5407.
34. Schneiderman JH, Sharpe JA, Sutton DM: Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol 1979;5:331-337.
35. Younes-Mhenni S, Derex L, Berruyer M, et al: Large-artery stroke in a young patient with Crohn's disease. Role of vitamin B 6 deficiency-induced hyperhomocysteinemia. J Neurol Sci 2004;221:113-115.
36. Levy PJ, Tabares AH, Olin JW: Lower extremity arterial occlusions in young patients with Crohn's colitis and premature atherosclerosis: report of six cases. Am J Gastroenterol 1997;92:494-497.
37. Novotny DA, Rubin RJ, Slezak FA, Porter JA: Arterial thromboembolic complications of inflammatory bowel disease. Report of three cases. Dis Colon Rectum 1992;35:193-196.
38. Ashkan K, Nasim A, Sayers RD, Dennis MJ: Arterial thrombosis: a complication of loop ileostomy. Eur J Gastroenterol Hepatol 1998; 10:795-796.
39. Efremidis M, Prappa E, Kardaras F: Acute myocardial infarction in a young patient during an exacerbation of ulcerative colitis. Int J Cardiol 1999;70:211-212.
40. Mutlu B, Ermeydan CM, Enc F, et al: Acute myocardial infarction in a young woman with severe ulcerative colitis. Int J Cardiol 2002;83:183-185.
41. Szychta P, Reix T, Sevestre MA, Brazier F, Pietri J: Aortic thrombosis and ulcerative colitis. Ann Vasc Surg 2001;15:402-404.
42. Novacek G, Haumer M, Schima W, et al: Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature. Inflamm Bowel Dis 2004;10:430-435.
43. Papa A, Santoliquido A, Danese S, et al: Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005;22:839-846.
44. Carty E, MacEy M, Rampton DS: Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1169-1179.
45. Thomas G, Skrinska VA, Lucas FV: The influence of glutathione and other thiols on human platelet aggregation. Thromb Res 1986;44:859-866.
46. Hommes DW, van Dullemen HM, Levi M, et al: Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease. Haemostasis 1997;27:269-277.
47. Danese S, Sans M, Scaldaferri F, et al: TNFalpha blockade downregulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006;176:2617-2624.
48. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A: Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11:7227-7236.
49. Koutroubakis IE: Therapy insight: vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:266-272.
50. Carty E, Rampton DS, Schneider H, Rutgeerts P, Wright JP: Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multicentre clinical trial in active Crohn's disease. Aliment Pharmacol Ther 2001;15:1323-1329.
51. Tytgat GN, Van Nueten L, Van De Velde I, Joslyn A, Hanauer SB: Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther 2002;16:87-99.
52. 2/prostaglandin H 2 receptor antagonists. A new therapeutic principle. Stroke 1990;21(suppl):139-142.
53. Panes J, Esteve M, Cabre E, et al: Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology 2000;119:903-908.
54. Saibeni S, Spina L, Signorelli C, et al: Safety and efficacy of oral, colonic-release, low-molecular-weight heparin-MMx™ for the treatment of mild to moderate left-sided ulcerative colitis: preliminary report of a pilot study. Gut 2006;55(suppl 5):A129.